H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, vol.27, pp.4733-4740, 2009.

T. N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce et al., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, vol.27, pp.740-745, 2009.

W. Taal, H. M. Oosterkamp, A. M. Walenkamp, H. J. Dubbink, L. V. Beerepoot et al., Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, vol.15, issue.14, pp.70314-70320, 2014.

W. Wick, T. Gorlia, M. Bendszus, M. Taphoorn, F. Sahm et al., Lomustine and bevacizumab in progressive glioblastoma, N Engl J Med, vol.377, pp.1954-1963, 2017.

P. Rana, K. I. Pritchard, and R. Kerbel, Plasma vascular endothelial growth factor as a predictive biomarker: door closed?, Eur J Cancer, vol.70, pp.143-145, 2017.

P. Baumgarten, A. E. Blank, K. Franz, E. Hattingen, M. Dunst et al., Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas, Neuro Oncol, vol.18, pp.173-183, 2016.

L. Erdem-eraslan, M. J. Van-den-bent, Y. Hoogstrate, H. Naz-khan, A. Stubbs et al., Identification of patients with recurrent glioblastoma who may benefit from combined bevacizumab and CCNU therapy: a report from the BELOB trial, Cancer Res, vol.76, pp.525-534, 2016.

J. Laffaire, D. Stefano, A. L. Chinot, O. Idbaih, A. et al., An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas, Biomed Res Int, p.282815, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01308273

J. Hayes, H. Thygesen, W. Gregory, D. R. Westhead, P. J. French et al., A validated micro-RNA profile with predictive potential in glioblastoma patients treated with bevacizumab, Mol Oncol, vol.10, pp.1296-1304, 2016.

T. Urup, S. R. Michaelsen, L. R. Olsen, A. Toft, I. J. Christensen et al., Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients, Mol Oncol, vol.10, pp.1160-1168, 2016.

L. B. Rivera, D. Meyronet, V. Hervieu, M. J. Frederick, E. Bergsland et al., Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy, Cell Rep, vol.11, pp.577-591, 2015.

M. Terme, S. Pernot, E. Marcheteau, F. Sandoval, N. Benhamouda et al., VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer, Cancer Res, vol.73, pp.539-549, 2013.

O. Adotevi, H. Pere, P. Ravel, N. Haicheur, C. Badoual et al., A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients, J Immunother, vol.33, pp.991-998, 2010.

S. Du-four, S. K. Maenhout, D. Benteyn, D. Keersmaecker, B. Duerinck et al., Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion, Cancer Immunol Immunother, vol.65, pp.727-740, 2016.

K. L. Pitter, I. Tamagno, K. Alikhanyan, A. Hosni-ahmed, S. S. Pattwell et al., Corticosteroids compromise survival in glioblastoma, Brain, vol.139, pp.1458-1471, 2016.

M. Nakagawa, T. Terashima, D. 'yachkova, Y. Bondy, G. P. Hogg et al., Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes, Circulation, vol.98, pp.2307-2313, 1998.

S. Massena, G. Christoffersson, E. Vagesjo, C. Seignez, K. Gustafsson et al., Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans, Blood, vol.126, pp.2016-2026, 2015.

J. Liang, Y. Piao, L. Holmes, G. N. Fuller, V. Henry et al., Neutrophils promote the malignant glioma phenotype through S100A4, Clin Cancer Res, vol.20, pp.187-198, 2014.

T. R. Sippel, J. White, K. Nag, V. Tsvankin, M. Klaassen et al., Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I, Clin Cancer Res, vol.17, pp.6992-7002, 2011.

O. Marini, S. Costa, D. Bevilacqua, F. Calzetti, N. Tamassia et al., Mature CD10(+) and immature CD10(?) neutrophils present in G-CSF-treated donors display opposite effects on T cells, Blood, vol.129, pp.1343-1356, 2017.

P. R. Gielen, B. M. Schulte, E. D. Kers-rebel, K. Verrijp, S. A. Bossman et al., Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function, Neuro Oncol, vol.18, pp.1253-1264, 2016.

B. Raychaudhuri, P. Rayman, J. Ireland, J. Ko, B. Rini et al., Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma, Neuro Oncol, vol.13, pp.591-599, 2011.

M. Lopes, B. Carvalho, R. Vaz, and P. Linhares, Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme, J Neurooncol, vol.136, pp.173-180, 2018.

M. Mason, C. Maurice, M. G. Mcnamara, M. T. Tieu, Z. Lwin et al., Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival, J Neurooncol, vol.132, pp.463-471, 2017.

S. Han, Y. Liu, Q. Li, Z. Li, H. Hou et al., Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma, BMC Cancer, vol.15, p.617, 2015.

G. A. Alexiou, E. Vartholomatos, and S. Voulgaris, Prognostic value of neutrophil-to-lymphocyte ratio in patients with glioblastoma, J Neurooncol, vol.115, pp.521-522, 2013.

A. Bertaut, C. Truntzer, R. Madkouri, C. G. Kaderbhai, V. Derangere et al., Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01410048

V. Quillien, A. Lavenu, F. Ducray, M. O. Joly, O. Chinot et al., Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial, Oncotarget, vol.7, pp.61916-61929, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01358205

C. Badoual, S. Hans, W. H. Fridman, D. Brasnu, S. Erdman et al., Revisiting the prognostic value of regulatory T cells in patients with cancer, J Clin Oncol, vol.27, pp.5-6, 2009.

B. Shang, Y. Liu, and S. J. Jiang, Prognostic value of tumor-infiltrating FoxP3 + regulatory T cells in cancers: a systematic review and meta-analysis, Sci Rep, vol.5, p.15179, 2015.

W. H. Fridman, F. Pages, C. Sautes-fridman, and J. Galon, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, vol.12, pp.298-306, 2012.

Q. Yue, X. Zhang, H. X. Ye, Y. Wang, Z. G. Du et al., The prognostic value of Foxp3 + tumor-infiltrating lymphocytes in patients with glioblastoma, J Neurooncol, vol.116, pp.251-259, 2014.

A. A. Thomas, J. L. Fisher, G. J. Rahme, T. H. Hampton, U. Baron et al., Regulatory T cells are not a strong predictor of survival for patients with glioblastoma, Neuro Oncol, vol.17, pp.801-809, 2015.

S. Han, C. Zhang, Q. Li, J. Dong, Y. Liu et al., Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma, Br J Cancer, vol.110, pp.2560-2568, 2014.

K. S. Voo, M. Foglietta, E. Percivalle, F. Chu, D. Nattamai et al., Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma, Int J Cancer, vol.135, pp.2834-2846, 2014.

M. Glowala-kosinska, A. Chwieduk, J. Nieckula, M. Saduswojciechowska, S. Grosicki et al., Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma, Eur J Haematol, vol.91, pp.122-128, 2013.

A. Kotsakis, F. Koinis, A. Katsarou, M. Gioulbasani, D. Aggouraki et al., Prognostic value of circulating regulatory T cell subsets in untreated nonsmall cell lung cancer patients, Sci Rep, vol.6, p.39247, 2016.

R. J. Diaz, S. Ali, M. G. Qadir, D. La-fuente, M. I. Ivan et al., The role of bevacizumab in the treatment of glioblastoma, J Neurooncol, vol.133, pp.455-467, 2017.

E. Tabouret, F. Boudouresque, M. Barrie, M. Matta, C. Boucard et al., Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma, Neuro Oncol, vol.16, pp.392-399, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01707899